SCHEMBL4919604

SCHEMBL4919604

O=C(CCCC1CCN(C(=O)NCc2csc3ccccc23)CC1)NO

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 13/20 0.69
HDAC8 Q9BY41 11/20 0.69
HDAC1 Q13547 11/20 0.69
HDAC3 O15379 10/20 0.69
HDAC4 P56524 10/20 0.69
HDAC7 Q8WUI4 10/20 0.69
HDAC2 Q92769 10/20 0.69
HDAC10 Q969S8 10/20 0.69
HDAC11 Q96DB2 10/20 0.69
HDAC9 Q9UKV0 10/20 0.69
HDAC5 Q9UQL6 10/20 0.69
CHRM4 P08173 1/20 0.50
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.43
FAAH O00519 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MTNR1A P48039 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920110 0.87 HDAC3 (0.56) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4926463 0.82 HDAC3 (1.00) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4927450 0.82 OPRD1 (0.56) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4927440 0.82 OPRD1 (0.56) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4916373 0.81 HDAC8 (0.49) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4916389 0.81 HDAC8 (0.49) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4923924 0.81 HDAC3 (0.67) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4923890 0.81 HDAC1 (0.72) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4916670 0.81 HDAC3 (0.72) HDAC6HDAC8HDAC1HDAC3HDAC4
SCHEMBL4927223 0.81 HDAC3 (0.72) HDAC6HDAC8HDAC1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US claimed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP claimed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO claimed
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US disclosed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP disclosed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them HDAC1, HDAC8, HDAC9 HDAC6 11/4885HDAC8 2/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.